Evidence map›Paper›PMID 31243287›Full record

ArticleNature communications2019

TGFβ-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosis.

Jinbo Li, Akram Ayoub, Yan Xiu, Xiaoxiang Yin, James O Sanders, Addisu Mesfin, Lianping Xing, Zhenqiang Yao, Brendan F Boyce

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 85 citations in OpenAlex.

  1. A RANKLBone research · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Epigenetic Mechanisms in Osteoporosis: Exploring the Power of mJournal of cellular and molecular medicine · 2025
    Review
  10. Review
  11. Article
  12. [Ferroptosis-related genes in osteoporosis: a bioinformatics analysis andZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jinbo LiDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Akram AyoubDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Yan XiuDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Xiaoxiang YinDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.
James O SandersDepartment of Orthopaedics and Rehabilitation Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Addisu MesfinDepartment of Orthopaedics and Rehabilitation Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Lianping XingDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Zhenqiang YaoDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA. Zhenqiang_Yao@urmc.rochester.edu.
Brendan F BoyceDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA. Brendan_Boyce@urmc.rochester.edu.
University of Rochester Medical Center · US

Funding

Studies on the fate of the OsteoclastR01AR043510 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI BOYCE, BRENDAN F · 1995 to 2025
$8.4M
Rochester Resource-Based Center for Bone, Muscle and Orthopaedic Research (ROCSTARR) (Overall Application)P30AR069655 · NIAMS · UNIVERSITY OF ROCHESTER · PI Edward M. Schwarz · 2016 to 2026
$7.8M
Studies of TRAF3 in age-related low-level chronic inflammation and osteoporosisR01AG049994 · NIA · UNIVERSITY OF ROCHESTER · PI BOYCE, BRENDAN F, YAO, ZHENQIANG · 2016 to 2020
$1.6M
Study of osteoblast regulation in TNF-mediated bone lossR01AR063650 · NIAMS · UNIVERSITY OF ROCHESTER · PI XING, LIANPING · 2013 to 2016
$1.4M
Olympus NanoZoomer RS Whole Slide Imaging SystemS10RR027340 · NCRR · UNIVERSITY OF ROCHESTER · PI BOYCE, BRENDAN F · 2010 to 2010
$340k
NCRR NIH HHS S10 RR027340NIAMS NIH HHS P30 AR069655NIAMS NIH HHS R01 AR043510NIAMS NIH HHS R01 AR063650NIA NIH HHS R01 AG049994
6 · The paper itself

Abstract

Inflammaging induces osteoporosis by promoting bone destruction and inhibiting bone formation. TRAF3 limits bone destruction by inhibiting RANKL-induced NF-κB signaling in osteoclast precursors. However, the role of TRAF3 in mesenchymal progenitor cells (MPCs) is unknown. Mice with TRAF3 deleted in MPCs develop early onset osteoporosis due to reduced bone formation and enhanced bone destruction. In young mice TRAF3 prevents β-catenin degradation in MPCs and maintains osteoblast formation. However, TRAF3 protein levels decrease in murine and human bone samples during aging when TGFβ1 is released from resorbing bone. TGFβ1 induces degradation of TRAF3 in murine MPCs and inhibits osteoblast formation through GSK-3β-mediated degradation of β-catenin. Thus, TRAF3 positively regulates MPC differentiation into osteoblasts. TRAF3 deletion in MPCs activated NF-κB RelA and RelB to promote RANKL expression and enhance bone destruction. We conclude that pharmacologic stabilization of TRAF3 during aging could treat/prevent age-related osteoporosis by inhibiting bone destruction and promoting bone formation.

Indexed as

AgingAnimalsCell DifferentiationFemaleMaleMesenchymal Stem CellsMiceMice, Inbred C57BLMice, KnockoutOsteoblastsOsteoporosisTNF Receptor-Associated Factor 3Transforming Growth Factor betaTNF Receptor-Associated Factor 3Transforming Growth Factor beta

Identifiers

PMID31243287
PMCPMC6595054
OpenAlexW2953401387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.